Page last updated: 2024-10-25

cilostamide and Sensitivity and Specificity

cilostamide has been researched along with Sensitivity and Specificity in 2 studies

cilostamide: selective inhibitor of cyclic AMP phosphodiesterase & platelet aggregation; structure

Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Diamandis, P	1
Wildenhain, J	1
Clarke, ID	1
Sacher, AG	1
Graham, J	1
Bellows, DS	1
Ling, EK	1
Ward, RJ	1
Jamieson, LG	1
Tyers, M	1
Dirks, PB	1
Thomas, RE	1
Armstrong, DT	1
Gilchrist, RB	1

Clinical Trials (2)

Trial Overview

Trial	Enrollment	Study Type	Start Date	Status
Serum Levels of C Type Natriuretic Peptide in Reproductive Age, Perimenopausal and Postmenopausal Women[NCT04000815]	71 participants (Actual)	Interventional	2019-07-24	Completed
C Type Natriuretic Peptide and Polycystic Ovary Syndrome[NCT04006171]	90 participants (Actual)	Interventional	2019-07-15	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Correlation Between Serum CNP and Antral Follicle Count (AFC) in Groups 1 and 2

Correlation between serum CNP and antral follicle count (AFC) in groups 1 and 2 using Spearman test (NCT04000815)
Timeframe: Second or Third Day of Menstruation

Intervention	follicles (Mean)
Reproductive Age Women	14.2
Perimenopausal Women	8.33

Correlation Between Serum CNP and Estradiol Levels in Groups 1 and 2

Correlation of CNP vs. Estradiol levels in reproductive age and perimenopausal women (NCT04000815)
Timeframe: Second or Third Day of Menstruation

Intervention	pg/mL (Median)
Reproductive Age Women	41
Perimenopausal Women	22

Serum C Type Natriuretic Peptide Levels

The comparison of serum levels of C type natriuretic peptide among different age groups (NCT04000815)
Timeframe: Second or Third Day of Menstruation

Intervention	pg/ml (Median)
Reproductive Age Women	43.68
Perimenopausal Women	55.98
Postmenopausal Women	116.36

Correlation Between Serum CNP and Follicle Stimulating Hormone and Luteinizing Hormone Levels in Groups 1 and 2

Correlations between serum CNP vs Follicle Stimulating Hormone(FSH), CNP vs Luteinizing Hormone(LH) levels in groups 1 and 2 (NCT04000815)
Timeframe: Second or Third Day of Menstruation

Intervention	mIU/mL (Median)
	Follicle Stimulating Hormone	Luteinizing Hormone
Perimenopausal Women	13.12	5.16
Reproductive Age Women	5.28	5.71

Free Androgen Index of Participants

Free androgen index of participants were compared. It was calculated with the formula 100XTotal testosterone/Sex hormone binding globulin (NCT04006171)
Timeframe: Second or Third Day of Menstruation

Intervention	% of T testosterone per SHBG (Mean)
Women With Polycystic Ovary Syndrome	4.39
Healthy Women of Reproductive Age	1.55

Homeostatic Model Assessment of Insulin Resistance of Participants

homeostatic model assessment of insulin resistance of participants were compared. The calculation was made with formula Glucose X Insulin/405. (NCT04006171)
Timeframe: Second or Third Day of Menstruation-morning fasting

Intervention	HOMA-IR Index (Median)
Women With Polycystic Ovary Syndrome	1.50
Healthy Women of Reproductive Age	1.45

Roc Curve of CNP

We made a cut off value estimation for the diagnosis of PCOS by serum CNP levels using Receiver operator characteristics. The ROC curve incorporates both sensitivity (true positive rate) and specificity (true negative rate) providing a single assessment incorporating both measures. The higher the total area under the curve, the greater the predictive power of the CNP for diagnosing PCOS (NCT04006171)
Timeframe: Second or Third Day of Menstruation

Intervention	probability (Number)
All Participants	0.706

Serum Androstenedione Levels of PCOS and Healthy Women

Serum Androstenedione Levels of PCOS and Healthy Women were compared (NCT04006171)
Timeframe: Second or Third Day of Menstruation

Intervention	ng/dL (Mean)
Women With Polycystic Ovary Syndrome	148.89
Healthy Women of Reproductive Age	84.66

Serum CNP Levels of PCOS and Healthy Participants

The comparison of serum levels of C type natriuretic peptide among PCOS and healthy women (NCT04006171)
Timeframe: Second or Third Day of Menstruation

Intervention	pg/ml (Median)
Women With Polycystic Ovary Syndrome	110
Healthy Women of Reproductive Age	57

Serum Dehydroepiandrosterone Sulfate (DHEAS) Levels of PCOS and Healthy Women

Serum dehydroepiandrosterone sulfate (DHEAS) Levels of PCOS and Healthy Women were compared (NCT04006171)
Timeframe: Second or Third Day of Menstruation

Intervention	µg/dL (Median)
Women With Polycystic Ovary Syndrome	304.55
Healthy Women of Reproductive Age	299.95

Serum Estradiol Levels of PCOS and Healthy Women

Serum Estradiol levels of PCOS and Healthy Women were compared (NCT04006171)
Timeframe: Second or Third Day of Menstruation

Intervention	pg/mL (Median)
Women With Polycystic Ovary Syndrome	31
Healthy Women of Reproductive Age	36.5

Serum Free Testosterone Levels of PCOS and Healthy Women

Serum Free Testosterone Levels of PCOS and Healthy Women were compared (NCT04006171)
Timeframe: Second or Third Day of Menstruation

Intervention	pg/mL (Mean)
Women With Polycystic Ovary Syndrome	1.71
Healthy Women of Reproductive Age	1.12

Serum Insulin Levels of Participants

Serum Insulin Levels of Participants were compared (NCT04006171)
Timeframe: Second or Third Day of Menstruation-morning fasting

Intervention	mU/L (Median)
Women With Polycystic Ovary Syndrome	7.10
Healthy Women of Reproductive Age	7.10

Serum Prolactin Levels of PCOS and Healthy Women

serum prolactin levels of PCOS and healthy women were compared (NCT04006171)
Timeframe: Second or Third Day of Menstruation

Intervention	ng/mL (Mean)
Women With Polycystic Ovary Syndrome	17.21
Healthy Women of Reproductive Age	16.80

Serum Sex Hormone Binding Globulin Levels of PCOS and Healthy Women

Serum Sex Hormone Binding Globulin Levels of PCOS and Healthy Women were compared (NCT04006171)
Timeframe: Second or Third Day of Menstruation

Intervention	nmol/L (Median)
Women With Polycystic Ovary Syndrome	30.4
Healthy Women of Reproductive Age	59.4

Serum Tiroid Stimulating Hormone of PCOS and Healthy Women

serum tiroid stimulating hormone of PCOS and healthy women were compared (NCT04006171)
Timeframe: Second or Third Day of Menstruation

Intervention	mIU/L (Median)
Women With Polycystic Ovary Syndrome	1.61
Healthy Women of Reproductive Age	1.47

Serum Total Testosterone Levels of PCOS and Healthy Women

Serum Total Testosterone Levels of PCOS and Healthy Women were compared (NCT04006171)
Timeframe: Second or Third Day of Menstruation

Intervention	nmol/L (Mean)
Women With Polycystic Ovary Syndrome	1.38
Healthy Women of Reproductive Age	0.92

Comparison of FSH and LH of PCOS and Healthy Women

Serum FSH and LH of PCOS and healthy women were compared (NCT04006171)
Timeframe: Second or Third Day of Menstruation

Intervention	mIU/mL (Median)
	Follicle Stimulating Hormone	Luteinizing Hormone
Healthy Women of Reproductive Age	4.97	5.36
Women With Polycystic Ovary Syndrome	4.7	4.23

High Density Lipoprotein and Low Density Lipoprotein Levels of Participants

High density lipoprotein and low density lipoprotein levels of participants were compared (NCT04006171)
Timeframe: Second or Third Day of Menstruation-morning fasting

Intervention	mg/dL (Mean)
	High density lipoprotein	Low density lipoprotein
Healthy Women of Reproductive Age	62.15	92.92
Women With Polycystic Ovary Syndrome	53.82	98.50

Serum Glucose, Total Cholesterol and Triglycerides Levels of Participants

Serum glucose, total cholesterol and triglycerides levels of participants were compared (NCT04006171)
Timeframe: Second or third day of menstruation and morning fasting

Intervention	mg/dL (Median)
	Total cholesterol	triglycerides	Glucose
Healthy Women of Reproductive Age	171	77	89
Women With Polycystic Ovary Syndrome	164	78	88.5

Other Studies

2 other studies available for cilostamide and Sensitivity and Specificity

Article	Year
Chemical genetics reveals a complex functional ground state of neural stem cells. Nature chemical biology, 2007, Volume: 3, Issue:5 Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic	2007
Differential effects of specific phosphodiesterase isoenzyme inhibitors on bovine oocyte meiotic maturation. Developmental biology, 2002, Apr-15, Volume: 244, Issue:2 Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cattle; Cell Culture Techniques; Cells, Cultured; Cycl	2002
Differential effects of specific phosphodiesterase isoenzyme inhibitors on bovine oocyte meiotic maturation. Developmental biology, 2002, Apr-15, Volume: 244, Issue:2 Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cattle; Cell Culture Techniques; Cells, Cultured; Cycl	2002
Differential effects of specific phosphodiesterase isoenzyme inhibitors on bovine oocyte meiotic maturation. Developmental biology, 2002, Apr-15, Volume: 244, Issue:2 Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cattle; Cell Culture Techniques; Cells, Cultured; Cycl	2002
Differential effects of specific phosphodiesterase isoenzyme inhibitors on bovine oocyte meiotic maturation. Developmental biology, 2002, Apr-15, Volume: 244, Issue:2 Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cattle; Cell Culture Techniques; Cells, Cultured; Cycl	2002